STING1 and breast carcinoma: This finding aligns with previous research on NIPP effects in different cancer entities as well as other reports on different breast cancer therapies, such as radiotherapy, paclitaxel, and Olaparib, which similarly activate the STING pathway through DNA damage (22–24, 36).